Skip to main content

Table 3 Distribution of patients by REVEAL risk categories at baseline and ≥ 6-month time points in patients on macitentan

From: Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study

 

≥6-month

 

Baseline

1–7

8

9

10–11

≥12

Total

1–7

12

2

0

0

0

14

8

5

2

3

0

0

10

9

3

3

6

0

0

12

10–11

4

4

3

5

1

17

≥12

1

0

1

2

0

4

Total

25

11

13

7

1

57

  1. Risk categories: 1–7 low risk, 8 average risk, 9 moderate high risk, 10 or 11 high risk, and ≥ 12 very high risk
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us